Form 4: Esperion Therapeutics Executive Eric Warren Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Chief Commercial Officer Eric Warren sold 192 shares of Esperion Therapeutics (ESPR) common stock on May 17, 2024, to satisfy tax obligations related to vested restricted stock units.
Summary
- On May 17, 2024, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, Inc. (ESPR), sold 192 shares of common stock.
- The shares were sold at a price of $2.483 per share.
- The transaction was executed to cover tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Warren directly owns 168,126 shares of Esperion Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to a stock sale for tax purposes, which is a neutral event.
Industry Context
Sales of shares by company executives are a common occurrence, often related to compensation and tax planning. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2022/02/28 | Date of execution of the Limited Power of Attorney. |
| 2024/05/17 | Date of stock sale transaction. |
| 2024/05/20 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.